Výsledky vyhledávání - "William J, Eastman"

Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases

Autor: Craig, Leonardi, Baojin, Zhu, William N, Malatestinic, William J, Eastman, Jiaying, Guo, Mwangi J, Murage, Casey Kar-Chan, Choong, Russel, Burge, Andrew, Blauvelt

Publikováno v: Advances in Therapy. 39:3214-3224

Limited real-world data are available comparing multiple biologics on their adherence, persistence, and the use of concomitant biologics in the treatment of moderate-to-severe psoriasis in clinical practice. The objective was to compare persistence o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c453a7c39f55e66d77c7f49e4dc9477
https://doi.org/10.1007/s12325-022-02155-9

Zobrazit plný text záznamu

Value of PASI90 Versus Merit-Based Incentive Payment System Efficacy Measures

Autor: Jason E. Hawkes, Paulo Reis, Chen-Yen Lin, Talia Muram, William J. Eastman

Publikováno v: Journal of Psoriasis and Psoriatic Arthritis. 7:140-149

Background Achieving ≥90% improvement in Psoriasis Area and Severity Index (PASI90) is achievable with newer biologic therapies, such as ixekizumab. Standard of care payment systems such as the Merit-based Incentive Payment System (MIPS) responder

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::022adffd7a0a5669b874b6fcd2a7aa22
https://doi.org/10.1177/24755303221082623

Zobrazit plný text záznamu

S737 Mirikizumab Demonstrates Sustained Improvement in Fatigue in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies

Autor: Miguel Regueiro, Theresa Hunter Gibble, Alison Potts Bleakman, Xingyuan Li, Nathan Morris, William J. Eastman

Publikováno v: American Journal of Gastroenterology. 117:e518-e519

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::057cca5ca1f206441e5342fe9567855d
https://doi.org/10.14309/01.ajg.0000859588.88094.0d

Zobrazit plný text záznamu

Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)

Autor: Kim A. Papp, Kyoungah See, Bruce W Konicek, Sascha Gerdes, William J Eastman, Craig L. Leonardi, H. Elmaraghy, Missy McKean-Matthews, Heidi Crane

Publikováno v: Journal of drugs in dermatology : JDD. 20(8)

Background Long-term efficacy, safety, and quality of life with ixekizumab (IXE) through 5 years in UNCOVER-1 and UNCOVER-2 patients with baseline scalp, nail, or palmoplantar psoriasis were assessed. Methods Patients included in this intent-to-treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29027e55cc27297db094cedf37b211ec
https://pubmed.ncbi.nlm.nih.gov/34397207

Zobrazit plný text záznamu

Clinical response beyond the systemic lupus erythematosus responder index: Post-hoc analysis of the BLISS-SC study

Autor: William J Eastman, Milena Kurtinecz, N.L. Fox, Bonnie F Pobiner, William Stohl, Damon Bass, Ronald F van Vollenhoven, David Gordon, Richard Furie, J. Groark, Tania Gonzalez‑Rivera

Publikováno v: Lupus science & medicine, 5(1):e000288. BMJ Publishing Group
Lupus Science & Medicine

ObjectiveThe Systemic Lupus Erythematosus (SLE) Responder Index (SRI), developed as a primary outcome measure for use in clinical trials, captures improvement in SLE disease activity without concomitant worsening in disease manifestations. This study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc95843e2d0730ae51ccec5db37d2eed
https://pure.amc.nl/en/publications/clinical-response-beyond-the-systemic-lupus-erythematosus-responder-index-posthoc-analysis-of-the-blisssc-study(46485003-9e6f-45f1-b803-35bd8917c972).html

Zobrazit plný text záznamu

Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis

Autor: William J, Eastman, Steven, Malahias, John, Delconte, Dana, DiBenedetti

Publikováno v: Cutis. 94(1)

There is limited information available regarding patient preferences and attributes of topical product formulations for specific dermatologic conditions. This study focused on product attributes that were most desirable for 3 dermatologic conditions:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ca566387700f5a439e79d6e719060534
https://pubmed.ncbi.nlm.nih.gov/25101344

Zobrazit plný text záznamu

A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp

Autor: Steven R, Feldman, Mary, Mills, Thomas, Brundage, William J, Eastman

Publikováno v: Journal of drugs in dermatology : JDD. 12(3)

Calcipotriene ointment and cream are effective treatments for psoriasis, but many patients with scalp psoriasis prefer lighter, less messy vehicles.To evaluate the efficacy and safety of calcipotriene foam, 0.005%, for plaque-type psoriasis of the sc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cd965211a826c220beeadd7c137156e5
https://pubmed.ncbi.nlm.nih.gov/23545912

Zobrazit plný text záznamu

A randomized, double-blind phase 4 study of the efficacy and safety of ethanol-free clobetasol propionate foam, 0.05%, vs vehicle foam in the treatment of chronic hand dermatitis

Autor: Leon H, Kircik, William J, Eastman, Jennifer, Gwazdauskas

Publikováno v: Journal of drugs in dermatology : JDD. 12(3)

Chronic hand dermatitis may have a significant detrimental effect on daily home-related and work-related activities, and quality of life (QOL). Clobetasol propionate foam, 0.05%, is indicated for the treatment of inflammatory and pruritic manifestati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5aaa458617e8cb74a229d6334abf9605
https://pubmed.ncbi.nlm.nih.gov/23545917

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání